πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 822 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 9713599

Parenteral formulations of treprostinil

United Therapeutics Corporation Β· Granted Tue Jul 25 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 20 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9707284

Formulations of peptides and chloroquines for the treatment of pathogenic immune responses

The Regents of the University of California Β· Granted Tue Jul 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9707293

Stable aqueous formulations of adalimumab

Coherus BioSciences, Inc. Β· Granted Tue Jul 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9687448

Nucleic acid lipid particle formulations

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Jun 27 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 22 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9687527

Stable glucagon formulations for the treatment of hypoglycemia

The Regents of the University of Colorado, a Body Corporate Β· Granted Tue Jun 27 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 22 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9682033

Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Jun 20 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 15 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9682145

Stable aqueous formulations of adalimumab

Coherus BioSciences, Inc. Β· Granted Tue Jun 20 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 15 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9675692

Stabilized formulations containing anti-DLL4 antibodies

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jun 13 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 08 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9675639

Peroxide formulations and methods and applicators for using the same

Aclaris Therapeutics, Inc. Β· Granted Tue Jun 13 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 08 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9669076

Albumin-free factor VIII formulations

UNIVERSITY OF CONNECTICUT Β· Granted Tue Jun 06 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 01 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9662338

Formulations of viloxazine

Supernus Pharmaceuticals, Inc. Β· Granted Tue May 30 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 25 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9662396

Stable aqueous formulations of etanercept

Coherus BioSciences, Inc. Β· Granted Tue May 30 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 25 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9649364

Methods for producing stable therapeutic formulations in aprotic polar solvents

XERIS PHARMACEUTICALS, INC. Β· Granted Tue May 16 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 11 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9648899

Drinking water formulation and method and article relating to same

ESSENTIALIFE HOMEOPATHICS Β· Granted Tue May 16 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 11 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9636408

Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride

TONIX PHARMA LIMITED Β· Granted Tue May 02 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 27 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9636400

VEGF specific fusion protein antagonist formulations

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue May 02 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 27 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9629932

Photodynamic diagnosis, formulations usable as photosensitizers for this purpose, method f

SANOCHEMIA PHARMAZEUTIKA AG Β· Granted Tue Apr 25 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 20 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9623088

Factor VIII polypeptide formulations

BIOVERATIV THERAPEUTICS INC. Β· Granted Tue Apr 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9622983

Sustained-release formulations of topiramate

Supernus Pharmaceuticals, Inc. Β· Granted Tue Apr 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9616015

Formulations of human tissue kallikrein-1 for parenteral delivery and related methods

DiaMedica Inc. Β· Granted Tue Apr 11 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9610309

Liquid viral formulations

ONCOLYTICS BIOTECH INC. Β· Granted Tue Apr 04 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 30 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9610352

Lyophilized viral formulations

ONCOLYTICS BIOTECH INC. Β· Granted Tue Apr 04 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 30 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9603853

Formulations of viloxazine

Supernus Pharmaceuticals, Inc. Β· Granted Tue Mar 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9603907

Dry powder formulations of dNase I

Protalix Ltd. Β· Granted Tue Mar 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted